More News! 26 Nov 2019 Rare Inflammatory Disease Drug Beats Immunosuppressants in Phase III …disease than current treatments in a phase III trial. The drug avacopan was trialed in 331 patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. This life-threatening condition is also known as ANCA… November 26, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2019 €48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases …use the money to fund the first phase I trial for its lead antibody immunotherapy for the treatment of various kinds of solid and liquid tumors. The trial is expected… December 4, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2020 SynOx Joins Wave of Biotechs Attacking Solid Tumor ‘Comfort Zone’ …Celleron Therapeutics last week with a huge Series A round of €37M. The fledgling company is developing an antibody drug that Celleron licensed from Roche in August to treat a… November 23, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2020 Update: ADC Therapeutics’ IPO Hits Above Target with €215M …large B-cell lymphoma, and ultimately bring the drug to the US market. Lausanne-based ADC Therapeutics specializes in the development of antibody-drug conjugates, in which an antibody is attached to a… May 15, 2020 - 4 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 Sanofi drug reduces disease activity in relapsing MS New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a… June 1, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 30 Oct 2024 Could next-generation “switchable” CAR-T cells help improve the safety and efficacy of CAR-T therapies? …different methods can be used, but generally speaking, it involves giving the patient a separate administration of another substance – whether that be an existing drug or a novel antibody,… October 30, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Dec 2017 Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017 …now has a blockbuster feather in its cap: its multiple myeloma antibody, Darzalex, reached over $1B (€850M) in sales in November. (Janssen has exclusive rights to it, so Genmab received… December 5, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments? …an antibody targeting PGlu formation. So far, its Phase I clinical trials have returned encouraging data: patients receiving four injections over four months demonstrated a significant reduction in cognitive impairment…. December 19, 2016 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2021 Cancer Research UK Cuts Two Biotech Collaborations Amid Pandemic Squeeze …the original deal, CRUK would fund and conduct part of the clinical development of BioInvent’s lead antibody drug in exchange for milestone payments and royalties from the Swedish company. Under… February 16, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
In Depth 14 Apr 2023 mRNA vaccines: a promising future …vaccine that applies a similar mechanism whereby host cells are instructed to make copies of spike proteins to induce an immune response for antibody production. The first COVID 19 vaccine… April 14, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 7 May 2019 Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets …me. “Our technology uses antibody fragments that stabilize and push the GPCR into the active state while maintaining the natural sensitivity of the receptor.” Once the GPCR is locked… May 7, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 ‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small… January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email